Llwytho...
HER-2/neu overexpression in breast cancer
Background: In breast carcinoma, amplification &/or over-expression of HER-2/neu has been associated with a group of unfavorable prognostic factors. The Food & Drug Administration Agency approved Trastuzumab (Herceptin) for the therapy of metastatic breast cancer but only in patients with am...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Faculty of Medicine University of Baghdad
2010-10-01
|
| Cyfres: | مجلة كلية الطب |
| Pynciau: | |
| Mynediad Ar-lein: | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/977 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|